Crystal structure of a cytochrome P450 2B6 genetic variant in complex with the inhibitor 4-(4-chlorophenyl)imidazole at 2.0-A resolution
- PMID: 20061448
- PMCID: PMC2845937
- DOI: 10.1124/mol.109.062570
Crystal structure of a cytochrome P450 2B6 genetic variant in complex with the inhibitor 4-(4-chlorophenyl)imidazole at 2.0-A resolution
Abstract
The structure of the K262R genetic variant of human cytochrome P450 2B6 in complex with the inhibitor 4-(4-chlorophenyl)imidazole (4-CPI) has been determined using X-ray crystallography to 2.0-A resolution. Production of diffraction quality crystals was enabled through a combination of protein engineering, chaperone coexpression, modifications to the purification protocol, and the use of unique facial amphiphiles during crystallization. The 2B6-4-CPI complex is virtually identical to the rabbit 2B4 structure bound to the same inhibitor with respect to the arrangement of secondary structural elements and the placement of active site residues. The structure supports prior P450 2B6 homology models based on other mammalian cytochromes P450 and is consistent with the limited site-directed mutagenesis studies on 2B6 and extensive studies on P450 2B4 and 2B1. Although the K262R genetic variant shows unaltered binding of 4-CPI, altered binding affinity, kinetics, and/or product profiles have been previously shown with several other ligands. On the basis of new P450 2B6 crystal structure and previous 2B4 structures, substitutions at residue 262 affect a hydrogen-bonding network connecting the G and H helices, where subtle differences could be transduced to the active site. Docking experiments indicate that the closed protein conformation allows smaller ligands such as ticlopidine to bind to the 2B6 active site in the expected orientation. However, it is unknown whether 2B6 undergoes structural reorganization to accommodate bulkier molecules, as previously inferred from multiple P450 2B4 crystal structures.
Figures






Similar articles
-
Structures of cytochrome P450 2B6 bound to 4-benzylpyridine and 4-(4-nitrobenzyl)pyridine: insight into inhibitor binding and rearrangement of active site side chains.Mol Pharmacol. 2011 Dec;80(6):1047-55. doi: 10.1124/mol.111.074427. Epub 2011 Aug 29. Mol Pharmacol. 2011. PMID: 21875942 Free PMC article.
-
Structure of mammalian cytochrome P450 2B4 complexed with 4-(4-chlorophenyl)imidazole at 1.9-A resolution: insight into the range of P450 conformations and the coordination of redox partner binding.J Biol Chem. 2004 Jun 25;279(26):27294-301. doi: 10.1074/jbc.M403349200. Epub 2004 Apr 20. J Biol Chem. 2004. PMID: 15100217
-
Conformational adaptation of human cytochrome P450 2B6 and rabbit cytochrome P450 2B4 revealed upon binding multiple amlodipine molecules.Biochemistry. 2012 Sep 18;51(37):7225-38. doi: 10.1021/bi300894z. Epub 2012 Sep 4. Biochemistry. 2012. PMID: 22909231 Free PMC article.
-
Structure-function analysis of cytochromes P450 2B.Biochim Biophys Acta. 2007 Mar;1770(3):402-12. doi: 10.1016/j.bbagen.2006.07.006. Epub 2006 Jul 22. Biochim Biophys Acta. 2007. PMID: 16935426 Review.
-
Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6.Curr Drug Metab. 2009 Sep;10(7):730-53. doi: 10.2174/138920009789895534. Curr Drug Metab. 2009. PMID: 19702527 Review.
Cited by
-
Bioinformatics and variability in drug response: a protein structural perspective.J R Soc Interface. 2012 Jul 7;9(72):1409-37. doi: 10.1098/rsif.2011.0843. Epub 2012 May 2. J R Soc Interface. 2012. PMID: 22552919 Free PMC article. Review.
-
Tyrosine Nitration Contributes to Nitric Oxide-Stimulated Degradation of CYP2B6.Mol Pharmacol. 2020 Sep;98(3):267-279. doi: 10.1124/molpharm.120.000020. Mol Pharmacol. 2020. PMID: 32817462 Free PMC article.
-
Targeting of the highly conserved threonine 302 residue of cytochromes P450 2B family during mechanism-based inactivation by aryl acetylenes.Arch Biochem Biophys. 2011 Mar 1;507(1):135-43. doi: 10.1016/j.abb.2010.09.006. Epub 2010 Sep 15. Arch Biochem Biophys. 2011. PMID: 20836985 Free PMC article. Review.
-
Plasticity of CYP2B enzymes: structural and solution biophysical methods.Curr Drug Metab. 2012 Feb;13(2):167-76. doi: 10.2174/138920012798918417. Curr Drug Metab. 2012. PMID: 22208531 Free PMC article. Review.
-
Analysis of protein missense alterations by combining sequence- and structure-based methods.Mol Genet Genomic Med. 2020 Apr;8(4):e1166. doi: 10.1002/mgg3.1166. Epub 2020 Feb 25. Mol Genet Genomic Med. 2020. PMID: 32096919 Free PMC article.
References
-
- Bumpus NN, Sridar C, Kent UM, Hollenberg PF. (2005) The naturally occurring cytochrome P450 (P450) 2B6 K262R mutant of P450 2B6 exhibits alterations in substrate metabolism and inactivation. Drug Metab Dispos 33:795–802 - PubMed
-
- Chen CS, Lin JT, Goss KA, He YA, Halpert JR, Waxman DJ. (2004) Activation of the anticancer prodrugs cyclophosphamide and ifosfamide: identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics. Mol Pharmacol 65:1278–1285 - PubMed
-
- Collaborative Computational Project Number 4 (1994) The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 50:760–763 - PubMed
-
- Cosme J, Johnson EF. (2000) Engineering microsomal cytochrome P450 2C5 to be a soluble, monomeric enzyme: mutations that alter aggregation, phospholipid dependence of catalysis, and membrane binding. J Biol Chem 275:2545–2553 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases